Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy

Minke A. E. Rab, Jennifer Bos, Brigitte A. van Oirschot, Stephanie van Straaten, Penelope A. Kosinski, Victor Chubukov, Hyeryun Kim, Heidi Mangus, Roger E. G. Schutgens, Gerard Pasterkamp, Lenny Dang, Charles Kung, Eduard J. van Beers, Richard van Wijk

Blood (2021) 137 (21): 2997–3001.

https://doi.org/10.1182/blood.2020008635

Published: 2021

Includes: Supplemental data

Journal Articles

Characterization of Metabolic Response to AG-348, an Allosteric Activator of Red Cell Pyruvate Kinase, in Healthy Volunteers and Pyruvate Kinase Deficiency Patients

Victor Chubukov, Kendall Johnson, Penelope A Kosinski, Michelle Clasquin, Abhishek Jha, Hyeryun Kim, Thomas P Roddy, Elizabeth Merica, Ann J Barbier, Lenny Dang, Lee Silverman, Charles Kung

Blood (2016) 128 (22): 2452.

https://doi.org/10.1182/blood.V128.22.2452.2452

Published: 2016

Journal Articles

Population Pharmacokinetics and Pharmacodynamics of AG-348 in Healthy Human Volunteers Guide Dose Selection for the Treatment of Pyruvate Kinase Deficiency

Kha Le, PhD, Marvin Cohen, Yue Chen, Hyeryun Kim, Bruce Silver, Sam Agresta, MD, Elizabeth Merica, Charles Kung, Penelope Kosinski, Lee Silverman, Scott Biller, Hua Yang, PhD

Blood (2015) 126 (23): 3336.

https://doi.org/10.1182/blood.V126.23.3336.3336

Published: 2015

Journal Articles

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

Cyril Quivoron, Muriel David, Kim Straley, Jeremy Travins, Hyeryun Kim, Yue Chen, Dongwei Zhu, Véronique Saada, Olivia Bawa, Paule Opolon, Mélanie Polrot, Jean-Baptiste Micol, Christophe Willekens, Olivier Bernard, Hua Yang, Sam Agresta, Stéphane de Botton, Katharine Yen, Virginie Penard-Lacronique

Blood (2014) 124 (21): 3735.

https://doi.org/10.1182/blood.V124.21.3735.3735

Published: 2014

Journal Articles

AG-348 Activation of Pyruvate Kinase in Vivo Enhances Red Cell Glycolysis in Mice

Charles Kung, Collin Hill, Yue Chen, Abhishek Jha, Penelope Kosinski, Michelle Clasquin, Yaguang Si, Hyeryun Kim, Jeff Hixon, Lenny Dang, Sam Agresta, Lee Silverman, Hua Yang

Blood (2014) 124 (21): 4010.

https://doi.org/10.1182/blood.V124.21.4010.4010

Published: 2014

Journal Articles

Phase I Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects

Hua Yang, Elizabeth Merica, Yue Chen, Marvin Cohen, Ronald Goldwater, Collin Hill, Hyeryun Kim, Penelope Kosinski, Charles Kung, Bruce Silver, Luke Utley, Sam Agresta

Blood (2014) 124 (21): 4007.

https://doi.org/10.1182/blood.V124.21.4007.4007

Published: 2014

Journal Articles

IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels

Sophia Adamia, PhD, Patricia Toniolo, PhDcandidate, Amir T. Fathi, MD, Ilene Galinsky, ANP, Suiyang Liu, Katharine Yen, Hyeryun Kim Kim, Dongwei Zhu, Straley Kim, Martha Wadleigh, MD, David P. Steensma, MD, Ibiayi Dagogo-Jack, MD, Daniel J. DeAngelo, MD PhD, James D. Griffin, MD, Richard M. Stone, MD

Blood (2014) 124 (21): 1060.

https://doi.org/10.1182/blood.V124.21.1060.1060

Published: 2014

NARROW

Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy

Characterization of Metabolic Response to AG-348, an Allosteric Activator of Red Cell Pyruvate Kinase, in Healthy Volunteers and Pyruvate Kinase Deficiency Patients

Population Pharmacokinetics and Pharmacodynamics of AG-348 in Healthy Human Volunteers Guide Dose Selection for the Treatment of Pyruvate Kinase Deficiency

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

AG-348 Activation of Pyruvate Kinase in Vivo Enhances Red Cell Glycolysis in Mice

Phase I Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects

IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels

Email alerts

ASH Publications

American Society of Hematology

Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy

Characterization of Metabolic Response to AG-348, an Allosteric Activator of Red Cell Pyruvate Kinase, in Healthy Volunteers and Pyruvate Kinase Deficiency Patients

Population Pharmacokinetics and Pharmacodynamics of AG-348 in Healthy Human Volunteers Guide Dose Selection for the Treatment of Pyruvate Kinase Deficiency

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

AG-348 Activation of Pyruvate Kinase in Vivo Enhances Red Cell Glycolysis in Mice

Phase I Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects

IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only